Adam Pyrzak

Adam Pyrzak

Auto-generated profile, based on publicly available information

Adam Pyrzak

Northwestern University Feinberg School of Medicine, Chicago, IL

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Open access
CPChristianne Persenaire
Christianne Persenaire
APAdam Pyrzak
Adam Pyrzak
EBEmma L. Barber
Emma L. Barber
To evaluate the effect of surgical approach on overall survival (OS) for women with advanced, epithelial ovarian cancer (EOC) following neoadjuvant chemotherapy (NACT) and determine the socio-demographic and clinical factors associated with surgical approach. The primary exposure was surgical approach to interval cytoreduction, minimally invasive versus open, and was evaluated by intention to treat. Primary outcome was OS. Associations were examined using Chi-squared tests, Wilcoxon rank sum tests, and multivariate logistic regression. Survival analysis was performed with Kaplan-Meier methods and Cox proportional hazards. The National Cancer Database was used to identify women diagnosed with stage IIIC/IV EOC from 2010–2016. Patients were included if they were treated with NACT within 90 days of diagnosis prior to interval cytoreductive surgery (CRS). 8,085 women were identified; 6,713 (83%) underwent open interval CRS and 1,372 (17%) underwent minimally invasive interval CRS. The proportion undergoing minimally invasive CRS after NACT increased from 2% in 2010 to 11% in 2016, a nearly 6-fold increase. There was no difference in OS between women who underwent minimally invasive and open interval CRS (median OS 36.5 vs 35.2 months, HR 0.94, 95% CI 0.86–1.04). After adjusting for demographic and clinical variables, including age, race, ethnicity, income, and Charlson/Deyo score, no difference in OS was observed (HR 0.95, 95% CI 0.86–1.04). Women of older age (OR 1.35, 95% CI 1.05–1.74) and Hispanic ethnicity (OR 1.46, 95% CI 1.14–1.88) had increased odds of receiving minimally invasive CRS following NACT, while low income (<$38,000/year) women had decreased odds (OR 0.76, 95% CI 0.60–0.97, p=0.03). Length of stay differed for patients undergoing minimally invasive versus open interval CRS (3 vs 5 days, p<0.01), but there was no difference in need for postoperative readmission. Minimally invasive CRS has similar survival outcomes to open CRS among women with EOC who have undergone NACT.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DMDavid Mysona
David Mysona
APAdam Pyrzak
Adam Pyrzak
JAJennifer Allen
Jennifer Allen
SBShan Bai
Shan Bai
ASAshok Sharma
Ashok Sharma
SGSharad A. Ghamande
Sharad A. Ghamande
E17005 Background: Cervical cancer is the second most common cancer of women worldwide. In this prospective study, we attempted to identify a set of serum biomarkers, which could identify patients who have invasive cervical cancer and monitor disease status (progression of disease (PD), remission (RM)). Biomarker selection focused on the matrix metalloproteinase (MMP) family and growth factors. Methods: In this IRB approved prospective study, luminex bead array was used to measure serum protein concentrations of 19 selected proteins in cervical cancer patients (CC) (n=23) compared to women with precancerous lesions (CIN2-3) (n=20), and patients with normal cervical cytology (n=20). Cervical cancer (adenocarcinoma and squamous carcinoma) patients had blood samples drawn within 30 days of diagnosis and repeat blood samples taken on follow up after completing therapy. Results were correlated to clinical data and outcomes. MMP7 expression was confirmed by immunohistochemistry (IHC). IHC scoring was done blindly by two pathologists independently. Results: Six proteins (CA153, OPG, CEA, IGFBP7, IGFBP4, and MMP-7) had significantly different levels in CC patients compared to controls and CIN (p < 0.05). MMP-7 had a sensitivity of 92% at 95% specificity. IHC revealed significant staining of MMP7 below the epithelial basement membrane of CC samples when compared to CINs and controls P<0.05. There was no difference in staining intensity between CINs, controls, and CC patients. MMP7 has significantly altered expression when comparing RM and PD (P<0.05). It also was an indicator of progression free survival (HR:4.5, P<0.05) and an indicator of overall survival at PD (P value = 0.04, HR= 7.5). Conclusions: MMP7 serum concentration is significantly altered when comparing CC patients to controls and CINs. This may be due to the overwhelming expression of MMP7 below the basement membrane in invasive CC. Further studies warrant investigating MMP7’s role in CC.